Initiative

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 9, 2024
Uber, News, Neurobiology of Aging, Form, Apoptosis, IPO, Health, Particulates, Cassava Sciences, City University, P.C, Electrode, ALS, Register, Initiative, Cassava, AMX0035, Journal, Graphite, IBD, Evercore, EAF, Amyotrophy, Environment, DoorDash, Complaint, Safety, Biomarker, Public expenditure, Sustainable development, Amylyx Pharmaceuticals, Science, Prescription, Prospectus, GrafTech, Reuters, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Government, Patient, Cognition, Defendant, Pharmaceutical industry

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.

Key Points: 
  • The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.
  • The Company offers its services through a mobile application and website, while also providing software-as-a-service solutions to retailers.
  • In addition, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on: 
Thursday, March 7, 2024
Pomerantz, City University, Court, Person, FDA, Prior, News, Data management, Neurobiology of Aging, Complaint, District court, Ext, Initiative, Safety, Cassava, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, Action Replay, Pharmaceutical industry

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Thursday, March 7, 2024
Scientific misconduct, Court, Alzheimer's disease, FDA, News, Advertising, Data management, Neurobiology of Aging, Initiative, Safety, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, City University, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, Amylyx, Sunnova, and DICK’S Sporting Goods and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 5, 2024
News, Neurobiology of Aging, Commerce, Apoptosis, The Washington Free Beacon, Energy, Sunnova, DOE, Cassava Sciences, State, City University, P.C, House Committee, ALS, Initiative, Cassava, AMX0035, Journal, Electricity, IBD, Evercore, Amyotrophy, Complaint, Safety, NOVA, Biomarker, Amylyx Pharmaceuticals, Outdoor, Science, Prescription, Scientific misconduct, BBC World Service, Alzheimer's disease, DKS, FDA, Food, Data management, Investor's Business Daily, Nature, Letter, Risk, Natural Resources, Patient, Cognition, Defendant, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • Then, on August 22, 2023, Dick’s Sporting Goods revealed that profitability for the second quarter of 2023 was significantly lower than previously represented.
  • Dick’s Sporting Goods also lowered its profitability guidance for the rest of fiscal year 2023.
  • For more information on the DICK’S Sporting Goods class action go to: https://bespc.com/cases/DKS

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Friday, March 1, 2024
Scientific misconduct, Court, Alzheimer's disease, FDA, News, Advertising, Data management, Neurobiology of Aging, Initiative, Safety, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, City University, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024
Boeing, News, Fraud, Neurobiology of Aging, Apoptosis, Cassava Sciences, MAX, City University, P.C, ALS, Initiative, Cassava, AMX0035, Journal, IBD, Security (finance), Evercore, Amyotrophy, Alaska Airlines, BROG, BIA, Complaint, Safety, Biomarker, Crash, Amylyx Pharmaceuticals, Science, Prescription, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Gaping, Risk, Patient, Cognition, Defendant, Pharmaceutical industry

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.

Key Points: 
  • Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.
  • Throughout the Class Period, Defendants continued to assure investors that Boeing was laser-focused on safety and quality.
  • These false and misleading statements caused Boeing stock to trade at artificially inflated prices during the Class Period.
  • Also, according to the filed complaint, it took a near disaster to expose this heightened safety risk.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on: 
Wednesday, February 28, 2024
Pomerantz, City University, Court, Person, FDA, Prior, News, Data management, Neurobiology of Aging, Complaint, District court, Ext, Initiative, Safety, Cassava, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, Action Replay, Pharmaceutical industry

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, February 26, 2024
Boeing, News, Fraud, Neurobiology of Aging, Apoptosis, Cassava Sciences, MAX, City University, P.C, ALS, Initiative, Cassava, AMX0035, Journal, IBD, Security (finance), Evercore, Amyotrophy, Alaska Airlines, BROG, BIA, Complaint, Safety, Biomarker, Crash, Amylyx Pharmaceuticals, Science, Prescription, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Gaping, Risk, Patient, Cognition, Defendant, Pharmaceutical industry

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.

Key Points: 
  • Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.
  • Throughout the Class Period, Defendants continued to assure investors that Boeing was laser-focused on safety and quality.
  • These false and misleading statements caused Boeing stock to trade at artificially inflated prices during the Class Period.
  • Also, according to the filed complaint, it took a near disaster to expose this heightened safety risk.

CASSAVA SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options

Retrieved on: 
Friday, February 23, 2024
Scientific misconduct, Court, Alzheimer's disease, FDA, News, Advertising, Data management, Neurobiology of Aging, Woman, Initiative, Safety, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, City University, Pharmaceutical industry

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) and reminds investors of the April 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $100,000 investing in Cassava stock or options between August 18, 2022 and October 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 22, 2024
Scientific misconduct, City University, ALS, BBC World Service, Alzheimer's disease, Cassava Sciences, FDA, News, Food, Data management, Investor's Business Daily, Neurobiology of Aging, Complaint, Apoptosis, Safety, Initiative, Cassava, AMX0035, Biomarker, Patient, Cognition, Journal, Amylyx Pharmaceuticals, IBD, Evercore, Science, Defendant, Amyotrophy, Prescription, P.C, Pharmaceutical industry

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX